Co-Authors
This is a "connection" page, showing publications co-authored by Paolo Scarpellini and Alberto Zangrillo.
Connection Strength
1.518
-
Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. J Cardiothorac Vasc Anesth. 2021 Dec; 35(12):3631-3641.
Score: 0.231
-
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020 08; 217:108509.
Score: 0.222
-
Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit. JAMA. 2020 Jun 09; 323(22):2338-2340.
Score: 0.222
-
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency Crit Care Resusc. 2020 04 01; 22(2):91-94.
Score: 0.219
-
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
Score: 0.110
-
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2021 May 17; 11(1):10699.
Score: 0.059
-
Quantitative assessment of lung involvement on chest CT at admission: Impact on hypoxia and outcome in COVID-19 patients. Clin Imaging. 2021 Sep; 77:194-201.
Score: 0.059
-
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
Score: 0.058
-
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020 12 04; 10(1):21291.
Score: 0.057
-
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021 Mar; 27(3):451-457.
Score: 0.057
-
Biobanking for COVID-19 research. Panminerva Med. 2020 Oct 19.
Score: 0.057
-
Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. PLoS One. 2020; 15(10):e0239570.
Score: 0.057
-
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
Score: 0.055
-
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
Score: 0.055